Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This review explores the complex role of the Innate Immune System in rheumatoid arthritis, highlighting gaps in understanding its functions and interactions with the Adaptive Immune System, offering insights into potential biomarkers and therapeutic strategies for this challenging autoimmune condition.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

This study found that valproic acid is effective in controlling absence seizures and can improve other seizure types, but 20% of patients experience mostly transient adverse reactions.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study reports that valproic acid is effective in treating absence seizures and shows improvement in other types of seizures, though about 20% of patients experienced adverse effects.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This case report describes a cat that developed alopecia and hyperactivity after ingesting valproic acid from contaminated household food, with symptoms resolving after the drug was removed.

This study found that antiandrogenic therapy with Melleva 35 for three months was effective in reducing hair loss and improving acne in women with both Androgenetic Alopecia and Acne Vulgaris.

This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.

This case report diagnosed variegate porphyria in a 33-year-old woman based on significant laboratory abnormalities, but with clinical features resembling porphyria cutanea tarda.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

This scoping review aims to map current knowledge about treatment strategies for alopecia caused by VPA (valproic acid) across various patient groups, identifying reported management strategies, supporting evidence, observed outcomes, and areas needing further research, but results are not provided.

This study observed that valproic acid treatment led to a significant reduction in aggressive and impulsive behaviors among patients with acquired brain injury, with varying effects based on cognitive impairment degree; the treatment was generally well-tolerated, though some patients experienced temporary side effects.

This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

Low dose valproic acid treatment caused hair loss in a young patient.

In this observational study, AC5 reduced hair loss in 89% of subjects with mild androgenic alopecia, and was well tolerated and appreciated by most participants.

The adapalene-benzoyl peroxide gel works better and faster for acne treatment than using either ingredient alone, with manageable side effects.

This case report describes a 40-year-old woman who developed erythema annulare centrifugum, a type of skin rash, likely triggered by taking the drug aceclofenac.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.